Strides Pharma Science

Strides Pharma Science Capital Expenditures

The Capital Expenditures (CapEx) of Strides Pharma Science (STAR.NS) as of Oct 16, 2026 is -2.42 B INR. In the previous year, Capital Expenditures (CapEx) was -1.18 B INR — a change of 105.24% (lower).

Capital Expenditures

-2.42 BINR

YoY

105.24%

Last updated:

Capital Expenditures (CapEx) of Strides Pharma Science is 2025 -2.42 B INR. Capital Expenditures (CapEx) of Strides Pharma Science was 2024 -1.18 B INR. It decreases by 105.24% lower compared to the previous year.

The Strides Pharma Science Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-4.03 B INR
Jan 1, 2019
-3.29 B INR
Jan 1, 2020
-1.50 B INR
Jan 1, 2021
-2.97 B INR
Jan 1, 2022
-1.43 B INR
Jan 1, 2023
-949.38 M INR
Jan 1, 2024
-1.18 B INR
Jan 1, 2025
-2.42 B INR
The Strides Pharma Science Capital Expenditures history
YEARCapital ExpendituresYoY
-2.42 BINR+105.24%
-1.18 BINR+24.45%
-949.38 MINR-33.79%
-1.43 BINR-51.80%
-2.97 BINR+98.32%
-1.50 BINR-54.42%
-3.29 BINR-18.27%
-4.03 BINR-40.99%
-6.82 BINR+84.85%
-3.69 BINR+52.55%
-2.42 BINR-50.41%
-4.88 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd, trading under the ticker symbol STAR.NS and identified by ISIN INE939A01011, is a prominent entity within the Indian healthcare sector, specifically operating in the pharmaceuticals industry. Headquartered in Bangalore, Karnataka, the company has established itself as a significant player in the global market for generic and bio-pharmaceutical products. Strides Pharma Science Ltd went public on February 3, 2000, marking a pivotal moment in its corporate history and allowing it to expand its operational footprint. The organization currently employs approximately 2,850 full-time staff members who are dedicated to the development, manufacture, and distribution of its diverse product portfolio. The company’s business activities are primarily divided into two main segments: Pharmaceutical and Bio-pharmaceutical. This structural division allows the firm to focus on both traditional generic drugs and more complex biological therapeutics, ensuring a balanced approach to meeting varied market demands. Geographically, Strides Pharma Science Ltd has a broad international presence, serving markets across Africa, Australia, Asia excluding India, North America, Europe, India, and other regions. This extensive reach is supported by a robust manufacturing infrastructure comprising eight distinct units. These facilities are strategically located to optimize supply chain efficiency and regulatory compliance. In India, the company operates two manufacturing sites in Bengaluru, along with additional facilities in Puducherry and Chennai. Beyond its domestic operations, Strides maintains manufacturing capabilities in Singapore, Milan, Italy, Florida, United States, and Nairobi, Kenya. This global network enables the company to produce a wide array of dosage forms, including liquids, creams, ointments, soft gels, sachets, tablets, and modified-release formats. Notably, the company is also engaged in the specialized manufacturing of soft gelatin capsules. The firm’s product development strategy emphasizes intellectual property-led niche products, distinguishing it from competitors who may focus solely on standard generics. The therapeutic areas covered by Strides Pharma Science Ltd are extensive, with a strong emphasis on drugs for anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, as well as other infectious diseases. This focus on high-impact therapeutic segments underscores the company’s commitment to addressing critical global health challenges. By combining a strong manufacturing base with a diverse product range and a global distribution network, Strides Pharma Science Ltd continues to play a vital role in the pharmaceutical landscape, providing essential medicines to patients worldwide while maintaining its position as a key player in the Indian stock market. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

Capital Expenditures (CapEx) of Strides Pharma Science is -2.42 B INR in 2025.

Capital Expenditures (CapEx) of Strides Pharma Science changed from -1.18 B INR to -2.42 B INR, representing a 105.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Strides Pharma Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Strides Pharma Science

All Key Metrics — Strides Pharma Science